Thursday, November 7, 2013

A palliative Milton, Ontario woman pleads for funding of cancer drug

Avastin is covered for brain cancer treatment, specifically glioblastoma multiforme, in British Columbia, Saskatchewan and Manitoba.


That said, it seem nothing more than a lobby for a drug not approved by the government. Tax dollars are not limitless.
Some complain that our underfunded system, with top-heavy administration, should foot the bill.
I disagree. For two reasons.
We pay for administrators and they must do their jobs. Salaries are separate from drug benefits.
Also, this drug has not been proven to prolong a palliative patient's life.

The infusion treatment of Avastin takes six months, which she receives at a Burlington clinic, and costs $48,000 over that period. She has raised nearly $40,000 in the past 10 days.
The health minister also said she has confidence in Ontario’s evidence-based system of drug review and approval. 

What is Avastin approved to treat?

Glioblastoma (GBM) when taken alone in adult patients whose cancer has progressed after prior treatment. The effectiveness of Avastin in GBM is based on tumor response. Currently, no data have shown whether or not Avastin improves disease-related symptoms or survival in people previously treated for GBM.
Please see full Product Information, including Serious Side Effects, for additional important safety information. The most common side effects of Avastin are:
  • Nosebleeds
  • Headache
  • High blood pressure
  • Inflammation of the nose
  • Too much protein in the urine
  • Taste change
  • Dry skin
  • Rectal bleeding
  • Tear production disorder
  • Back pain
  • Inflammation of the skin

No comments: